Back to Journals » Diabetes, Metabolic Syndrome and Obesity » GLP-1 Agonists: The Game-Changers in Type 2 Diabetes and Obesity Care
Diabetes, Metabolic Syndrome and Obesity
- View all (3376)
- Volume 19, 2026 (114)
- Volume 18, 2025 (389)
- Volume 17, 2024 (428)
- Volume 16, 2023 (373)
- Volume 15, 2022 (350)
- Volume 14, 2021 (449)
- Volume 13, 2020 (486)
- Volume 12, 2019 (269)
- Volume 11, 2018 (92)
- Volume 10, 2017 (52)
- Volume 9, 2016 (45)
- Volume 8, 2015 (59)
- Volume 7, 2014 (61)
- Volume 6, 2013 (50)
- Volume 5, 2012 (41)
- Volume 4, 2011 (46)
- Volume 3, 2010 (45)
- Volume 2, 2009 (22)
- Volume 1, 2008 (5)
Journal Articles:
- From Type 1 to Type 2 Diabetes and Obesity: The Impact of Continuous Glucose Monitoring (CGM) and Emerging Diabetes Management Technologies on Metabolic Health (1)
- GLP-1 Agonists: The Game-Changers in Type 2 Diabetes and Obesity Care (4)
- The State of Diabetes, Metabolic Syndrome and Obesity (9)
- Managing obesity with pharmacotherapy (7)
- Understanding the Impact of Gender and Sex on Diabetes Incidence, Complications, and Treatment (1)
- Emerging therapeutic targets of diabetic nephropathy (1)
GLP-1 Agonists: The Game-Changers in Type 2 Diabetes and Obesity Care
Since their clinical introduction, GLP-1 receptor agonists have revolutionized patient care, offering significant benefits in glycemic control, weight loss and management, and cardiovascular and renal diseases for eligible patients. Given the recognized importance of GLP-1 agonists in managing type 2 diabetes and obesity, and the accumulating new evidence showing several pleiotropic effects, Diabetes, Metabolic Syndrome and Obesity here collects original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.
GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies
Alourfi NM, Alorfi NM
Diabetes, Metabolic Syndrome and Obesity 2026, 19:584052
Published Date: 3 February 2026
Community Pharmacists’ Knowledge and Counseling Competence on GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes Care in Türkiye: A Cross-Sectional Study
Bayram-Ozgur D, Demirtürk E, Sar Y
Diabetes, Metabolic Syndrome and Obesity 2026, 19:587750
Published Date: 3 March 2026
Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic Review
Xie Z, Liang Z, Xie Y, Zheng G, Cao W
Diabetes, Metabolic Syndrome and Obesity 2025, 18:2837-2849
Published Date: 12 August 2025
Effects of GLP-1RA Treatment on Long-Term Post-PCI Prognosis in T2DM Patients: A Propensity Score Matching Study
Fang B, Liu F, Luo J, Song N, Liu C, Ji W, An X, Xie Q, Yang Y, Li X
Diabetes, Metabolic Syndrome and Obesity 2025, 18:3031-3040
Published Date: 25 August 2025